Abstract
With the aim of objectively evaluating the efficacy, safety and usefulness of panipenem/betamipron (PAPM/BP) in the treatment of bacterial pneumonia, a comparative study using imipenem/cilastatin sodium (IPM/CS) as the control drug was undertaken, and the following results obtained. Either PAPM/BP or IPM/CS, in a dose of 1.0 g/1.0 g daily (in 2 divided doses), was administered for a duration of, in principle, 14 days. 1) Clinical efficacy: The efficacy rate in the judgement of the committee was 84.5% in the PAPM/BP group and 91.1% in the IPM/CS group, with no significant difference between the two groups. Judged by the physician in charge, the rate was 85.9% in the PAPM/BP group and 82.1% in the IPM/CS group, with no significant difference between the two groups. 2) Bacteriological efficacy: The eradication rate was 78.3% in the PAPM/BP group and 100% in the IPM/CS group, with no significant difference between the two groups. 3) Side effects and abnormal laboratory data: The incidence of side effects was 3.6% in the PAPM/BP group and 5.7% in the IPM/CS group. Abnormal laboratory data were found in 39.5% and 26.5% respectively, but none was serious and no significant difference was seen between the two groups. 4) Usefulness: The rate of usefulness was evaluated by the committee to be 83.1% in the PAPM/BP group and 85.7% in the IPM/CS group, with no significant difference between the two groups. Judged by the physician in charge, the rate was 84.5% in the PAPM/BP group and 83.6% in the IPM/CS group, with no significant difference between the two groups. These results confirm that the administration of PAPM/BP, 1.0 g/1.0 g daily in the treatment of bacterial pneumonia is as clinically useful as the administration of IPM/CS, 1.0 g/1.0 g daily.
Original language | English |
---|---|
Pages (from-to) | 509-531 |
Number of pages | 23 |
Journal | Chemotherapy |
Volume | 40 |
Issue number | 4 |
DOIs | |
Publication status | Published - 1992 Apr |
Externally published | Yes |
Keywords
- Bacterial pneumonia
- Comparative study
- IPM/CS
- PAPM/BP
- panipenem/betamipron
ASJC Scopus subject areas
- Pharmacology (medical)
- Infectious Diseases
- Pharmacology
- Drug Discovery
- Oncology